Jun 2026 (Q2 FY26) — Jul 30, 2026
Laureate Education Q2 FY26 — Strong Enrollment Growth and Raised Full-Year Outlook
Read the full callLaureate Education earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 616 | +17.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 36.3 | −0.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 137 | +44.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
1Y: $29.37 on 17 Oct 2025 → $39.3. High $40.46 (10 Jul 2026), low $28.88 (29 Oct 2025).
Overview
Call summaries
Laureate Education Q2 FY26 — Strong Enrollment Growth and Raised Full-Year Outlook
Read the full callLaureate Education Q1 FY26 — Strong Enrollment Growth in Peru and Increased EPS Guidance
Read the full callEvery analysed call
Financials
Net profit, year on year: +44% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 369 | 423 | 236 | 524 | 400 | 541 | 273 | 616 |
| Operating profit | 72 | 124 | -13 | 193 | 71 | 179 | -28 | 223 |
| Operating margin | 19.5% | 29.3% | −5.6% | 36.9% | 17.9% | 33.1% | −10.1% | 36.3% |
| Interest | 5 | 3 | 2 | 3 | 3 | 3 | 3 | 4 |
| Profit before tax | 85 | 139 | -17 | 167 | 69 | 183 | -27 | 219 |
| Tax rate | −0.6% | 33.3% | −14.6% | 41.6% | 50.1% | 6.0% | 20.9% | 37.3% |
| Net profit | 85 | 94 | -19 | 95 | 34 | 172 | -22 | 137 |
| EPS ($ per share) | 0.56 | — | -0.13 | 0.65 | 0.23 | — | -0.15 | 0.98 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | — | — | 1 | 1 | 1 | 1 | 1 |
| Reserves | -531 | 437 | -177 | 16 | 39 | 42 | 292 | 417 |
| Total liabilities | 4,704 | 3,680 | 2,705 | 1,070 | 1,196 | 1,176 | 904 | 1,018 |
| Fixed assets | 1,275 | 641 | 578 | 500 | 523 | 562 | 514 | 629 |
| Total assets | 6,770 | 6,496 | 4,971 | 2,211 | 1,972 | 2,126 | 1,862 | 2,206 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 397 | 340 | 260 | -156 | 178 | 251 | 233 | 366 |
| Cash from investing | 115 | 1,117 | 587 | 2,044 | 30 | -52 | -58 | -103 |
| Cash from financing | -410 | -1,674 | -273 | -2,683 | -462 | -202 | -167 | -222 |
| Net cash flow | 2 | -28 | 769 | -522 | -252 | 3 | 1 | 54 |
| Capital expenditure | -238 | -156 | -75 | -50 | -53 | -56 | -72 | -103 |
| Free cash flow | 159 | 184 | 185 | -207 | 125 | 194 | 161 | 263 |
Peru grew from 50% to 56% of revenue over the last two years.
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Peru | 50% | 47% | 20% | 59% | 51% | 49% | 23% | 56% | +13.1% |
| Mexico | 50% | 53% | 80% | 41% | 49% | 51% | 77% | 44% | +23.8% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
43 filings between Nov 4, 2025 and Sep 30, 2026.
Purchases
None
No insider bought shares.
Sales
$23.90M
9 sales by 4 insiders
22% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Also filed: 1 gift.
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Snow Ian Kendell | — | $19.10M | Sep 2, 2026 |
| Cardoso Marcelo | — | $2.50M | Mar 17, 2026 |
| Buskirk Richard M. | — | $2.08M | Mar 11, 2026 |
| RODIN JUDITH | — | $214.1K | Dec 8, 2025 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | MUNOZ GEORGE Director | Award | 556 | $21.2K |
| Sep 2, 2026 | Snow Ian Kendell Director | Sale | 427,019 | $15.48M |
| Sep 1, 2026 | Snow Ian Kendell Director | Sale | 2,654 | $101.2K |
| Aug 31, 2026 | Snow Ian Kendell Director | Sale | 91,556 | $3.52M |
| Jun 30, 2026 | MUNOZ GEORGE Director | Award | 585 | $21.2K |
| May 21, 2026 | Coulter Julian George Director | Award | 3,252 | $0 |
| May 21, 2026 | Mair Barbara Director | Award | 5,308 | $0 |
| May 21, 2026 | de Macedo Aristides Director | Award | 5,308 | $0 |
| May 21, 2026 | Snow Ian Kendell Director | Award | 5,308 | $0 |
| May 21, 2026 | RODIN JUDITH Director | Award | 361 | $11.9K |
| May 21, 2026 | Cohen Andrew B Director | Award | 7,849 | $0 |
| May 21, 2026 | DAVIS WILLIAM J Director | Award | 5,308 | $0 |
| May 21, 2026 | MUNOZ GEORGE Director | Award | 5,308 | $0 |
| May 21, 2026 | del Corro Pedro Director | Award | 5,308 | $0 |
| Mar 31, 2026 | MUNOZ GEORGE Director | Award | 609 | $21.2K |
| Mar 31, 2026 | RODIN JUDITH Director | Award | 609 | $21.2K |
| Mar 17, 2026 | Cardoso Marcelo EVP & CHIEF OPERATING OFFICER | Sale 10b5-1 plan | 7,300 | $247.5K |
| Mar 15, 2026 | Serck-Hanssen Eilif PRESIDENT & CEO | Tax withheld | 44,478 | $1.52M |
| Mar 15, 2026 | Buskirk Richard M. SVP & CHIEF FINANCIAL OFFICER | Tax withheld | 12,391 | $424.5K |
| Mar 15, 2026 | Brush Leslie S SVP, CHIEF LEGAL OFFICER | Tax withheld | 2,695 | $92.3K |
| Mar 15, 2026 | Knauer Gerard M. VP, ACCTG, GLOBAL CONTROLLER | Tax withheld | 1,124 | $38.5K |
| Mar 11, 2026 | Buskirk Richard M. SVP & CHIEF FINANCIAL OFFICER | Sale | 60,803 | $2.05M |
| Mar 11, 2026 | Buskirk Richard M. SVP & CHIEF FINANCIAL OFFICER | Option exercise | 2,803 | $21.4K |
| Mar 11, 2026 | Buskirk Richard M. SVP & CHIEF FINANCIAL OFFICER | Sale | 1,000 | $34.3K |
| Feb 6, 2026 | Brush Leslie S SVP, CHIEF LEGAL OFFICER | Award | 5,923 | $0 |
| Feb 6, 2026 | Serck-Hanssen Eilif PRESIDENT & CEO | Award | 52,486 | $0 |
| Feb 6, 2026 | Serck-Hanssen Eilif PRESIDENT & CEO | Award | 113,024 | $0 |
| Feb 6, 2026 | Cardoso Marcelo EVP & CHIEF OPERATING OFFICER | Award | 12,059 | $0 |
| Feb 6, 2026 | Knauer Gerard M. VP, ACCTG, GLOBAL CONTROLLER | Award | 1,212 | $0 |
| Feb 6, 2026 | Buskirk Richard M. SVP & CHIEF FINANCIAL OFFICER | Award | 10,671 | $0 |
| Feb 6, 2026 | Buskirk Richard M. SVP & CHIEF FINANCIAL OFFICER | Award | 26,884 | $0 |
| Feb 6, 2026 | Brush Leslie S SVP, CHIEF LEGAL OFFICER | Award | 9,795 | $0 |
| Jan 2, 2026 | Cardoso Marcelo EVP & CHIEF OPERATING OFFICER | Sale 10b5-1 plan | 6,543 | $219.5K |
| Dec 31, 2025 | Knauer Gerard M. VP, ACCTG, GLOBAL CONTROLLER | Tax withheld | 1,001 | $34.0K |
| Dec 31, 2025 | Buskirk Richard M. SVP & CHIEF FINANCIAL OFFICER | Tax withheld | 12,270 | $416.4K |
| Dec 31, 2025 | Brush Leslie S SVP, CHIEF LEGAL OFFICER | Tax withheld | 2,264 | $76.8K |
| Dec 31, 2025 | RODIN JUDITH Director | Award | 631 | $21.2K |
| Dec 31, 2025 | Serck-Hanssen Eilif PRESIDENT & CEO | Tax withheld | 38,699 | $1.31M |
| Dec 31, 2025 | MUNOZ GEORGE Director | Award | 631 | $21.2K |
| Dec 15, 2025 | MUNOZ GEORGE Director | Gift | 6,200 | $0 |
| Dec 12, 2025 | Serck-Hanssen Eilif PRESIDENT & CEO | Tax withheld | 52,510 | $1.72M |
| Dec 8, 2025 | RODIN JUDITH Director | Sale | 7,065 | $214.1K |
| Nov 4, 2025 | Cardoso Marcelo CHIEF OPERATING OFFICER | Sale | 70,000 | $2.03M |
| Sep 30, 2025 | RODIN JUDITH Director | Award | 673 | $21.2K |
| Sep 30, 2025 | MUNOZ GEORGE Director | Award | 673 | $21.2K |
| May 22, 2025 | del Corro Pedro Director | Award | 7,148 | $0 |
| May 22, 2025 | Cohen Andrew B Director | Award | 10,395 | $0 |
| May 22, 2025 | Snow Ian Kendell Director | Award | 7,148 | $0 |
| May 22, 2025 | DAVIS WILLIAM J Director | Award | 7,148 | $0 |
| May 22, 2025 | de Macedo Aristides Director | Award | 7,148 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow LAUREATE EDUCATION, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading